>

Eugene Washington - Johnson Johnson Independent Director

<div class='circular--portrait' style='background:#FF6600;color: white;font-size:3em;padding-top: 40px;;'>JNJ</div>
JNJ -- USA Stock  

Fiscal Quarter End: March 31, 2020  

  Director
Dr. A. Eugene Washington, M.D., M.Sc. is an Independent Director of the Company. He is currently Duke Universitys Chancellor for Health Affairs and the President and Chief Executive Officer of the Duke University Health System. Previously he was Vice Chancellor of Health Sciences, Dean of the David Geffen School of Medicine at UCLA Chief Executive Officer of the UCLA Health System and Distinguished Professor of Gynecology and Health Policy at UCLA. Prior to UCLA, he served as Executive Vice Chancellor and Provost at the University of California, San Francisco from 2004 to 2010. Dr. Washington cofounded UCSFs Medical Effectiveness Research Center for Diverse Populations in 1993 and served as Director until 2005. He was Chair of the Department of Obstetrics, Gynecology, and Reproductive Sciences at UCSF from 1996 to 2004. Dr. Washington also cofounded the UCSFStanford Evidencebased Practice Center and served as its first Director from 1997 to 2002. Prior to UCSF, Dr. Washington worked at the Centers for Disease Control and Prevention. Dr. Washington was elected to the National Academy of Sciences Institute of Medicine in 1997, where he served on its governing Council. He was founding Chair of the Board of Governors of the PatientCentered Outcomes Research Institute, served as a member of the Scientific Management Review Board for the NIH, and also served as Chair of the Board of Directors of both the California HealthCare Foundation and The California Wellness Foundation. Dr. Washington currently serves on the Boards of Directors of the Kaiser Foundation Hospitals and Kaiser Foundation Health Plan, Inc.
Age: 67  Director Since 2012      
732 214-0332  www.jnj.com

Management Efficiency

The company has 30.43 B in debt with debt to equity (D/E) ratio of 50.0 . This implies that the company may be unable to create cash to meet all of its financial commitments. Johnson Johnson has Current Ratio of 1.3 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Craig ThompsonMerck Company
2008
John MadiganGilead Sciences
2005
Katherine BaickerEli Lilly And Company
2011
Carla HillsGilead Sciences
N/A
Shantanu NarayenPfizer
2013
Vicki SatoBristol Myers Squibb Company
2017
Jose BaselgaBristol Myers Squibb Company
2018
Lynn ElsenhansGlaxoSmithKline PLC
2012
Michael EskewEli Lilly And Company
2008
Carolyn BertozziEli Lilly And Company
2017
Lewis CampbellBristol Myers Squibb Company
2014
JeanPhilippe CourtoisAstrazeneca PLC
2008
Fred WeissAllergan Plc
2013
Deborah DiSanzoAstrazeneca PLC
2017
Thomas FreymanAllergan Plc
2018
Jackson TaiEli Lilly And Company
2013
Cornelia BargmannAstrazeneca PLC
2015
Graham ChipchaseAstrazeneca PLC
2019
Adriane BrownAllergan Plc
2017
Jamere JacksonEli Lilly And Company
2016
Marc DunoyerAstrazeneca PLC
2013

Company Summary

Johnson Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. The company was incorporated in 1887 and is based in New Brunswick, New Jersey. Johnson Johnson operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange.Johnson Johnson (JNJ) is traded on BATS Exchange in USA. It is located in One Johnson and Johnson Plaza, New Brunswick, NJ 08933, United States and employs 135,100 people. Johnson Johnson is listed under Pharmaceutical Products category by Fama And French industry classification.

Johnson Johnson Leadership Team

A Washington, Independent DirectorView
Jennifer Doudna, Independent DirectorView
Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. CommitteeView
William Perez, Independent DirectorView
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication OfficerView
Marillyn Hewson, Independent DirectorView
Jorge Mesquita, Executive Vice President Worldwide Chairman - ConsumerView
Mary Coleman, Independent DirectorView
Michael Ullmann, VP, General Counsel and Member of Executive CommitteeView
Joaquin Duato, Executive Vice President Worldwide Chairman - PharmaceuticalsView
Kathy Wengel, Executive Vice President Chief Global Supply Chain OfficerView
Jennifer Taubert, Executive Vice President - Worldwide Chairman, PharmaceuticalsView
Mary Beckerle, Independent DirectorView
Sandra Peterson, Group Worldwide Chairman and Member of Executive CommitteeView
Scott Davis, DirectorView
Louise Mehrotra, Vice President Investor RelationsView
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical DevicesView
Ronald Williams, Independent DirectorView
Kathryn Wengel, Executive Vice President Chief Global Supply Chain OfficerView
D Davis, Independent DirectorView
Hubert Joly, DirectorView
Anne Mulcahy, Lead Independent DirectorView
Joseph Wolk, Chief Financial Officer, Executive Vice PresidentView
Thibaut Mongon, Executive Vice President Worldwide Chairman, ConsumerView
Ian Davis, Independent DirectorView
Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive CommitteeView
Mark McClellan, Independent DirectorView
Charles Prince, Independent DirectorView
Eugene Washington, Independent DirectorView
Dominic Caruso, CFO, VP of Fin. and Member of Executive CommitteeView
Peter Fasolo, Chief Human Resource Officer, Executive Vice PresidentView
Susan Lindquist, Independent DirectorView
Mark Weinberger, DirectorView

Stock Performance Indicators

Current Sentiment - JNJ

Johnson Johnson Investor Sentiment

Predominant part of Macroaxis users are currently bullish on Johnson Johnson. What is your judgment towards investing in Johnson Johnson? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Please also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. drill down to check world indexes.